×
Madan Mohan Rao

Madan Mohan Rao

Vice President - Quality & Compliance

Madan Mohan Rao joined our senior leadership team as the Vice President of Quality & Compliance. Madan joins us in our Hyderabad office. Madan has held various leadership positions in the last 10 years in the areas of Quality and Technical Services. Prior to joining Slayback, Madan was the Head of Quality for greenfield sterile injectables and non-sterile API facilities at Biological E in Hyderabad. His expertise is in making facilities ‘any time audit ready’. Before BE, he was the Head of Quality Assurance, Quality Control and Microbiology for three sterile manufacturing sites at Mylan, where he worked with third party consultants like Quantic and Lachman to lead successful US FDA inspection post warning letter to the sites.

Copyright ©2021 all rights reserved

Hydroxyprogesterone

On April 6, 2023, the U.S. Food and Drug Administration (FDA) issued a final decision ordering the withdrawal of the approval of Makena® (hydroxyprogesterone caproate injection, 250 milligrams (mg) per mL) and its generics. FDA recognizes that there is a supply of product that has already been distributed. Patients who have questions should talk to their healthcare provider. We recommend health care practitioners consider FDA’s conclusions.

If you have questions or concerns about receiving your therapy as prescribed, consult your healthcare provider.

https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena